Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KW-6500 (Apomorphine) Phase 2 in Parkinson's Disease
NCT00610103Phase 2Completed
- Sponsor
- Kyowa Kirin
- Start
- Nov 2007
- Primary completion
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing KW-6500 with Placebo (2 arms). Primary endpoint: Unified Parkinson's Disease Rating Scale Part 3. Started Nov 2007; status: completed.
02
Drugs
KW-6500
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00610103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00610103.